Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers

J Alzheimers Dis. 2023;94(2):483-489. doi: 10.3233/JAD-230156.

Abstract

In a large population-based cohort, we show not all heterozygous APOEɛ4 carriers are at increased risk for Alzheimer's disease (AD); a significantly higher AD proportion was only found for ɛ3/ɛ4, not ɛ2/ɛ4. Among ɛ3/ɛ4 carriers (24% in the cohort), the AD proportion differed considerably by polygenic risk score (PRS). In particular, the AD proportion was lower than the entire cohort for subjects in the bottom 20-percentile PRS and was higher than that of homozygous ɛ4 carriers for subjects at the top 5th-percentile PRS. Family history was no longer a significant predictor of AD risk after adjusting APOE and PRS.

Keywords: APOE; Alzheimer’s disease; UK Biobank; genetic counseling; polygenic risk score.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Apolipoprotein E4 / genetics
  • Apolipoproteins E / genetics
  • Heterozygote
  • Homozygote
  • Humans

Substances

  • Apolipoprotein E4
  • Apolipoproteins E